These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 12663625

  • 1. Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment.
    Lepore G, Dodesini AR, Nosari I, Trevisan R.
    Diabetes Care; 2003 Apr; 26(4):1321-2. PubMed ID: 12663625
    [No Abstract] [Full Text] [Related]

  • 2. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study.
    Bolli GB, Kerr D, Thomas R, Torlone E, Sola-Gazagnes A, Vitacolonna E, Selam JL, Home PD.
    Diabetes Care; 2009 Jul; 32(7):1170-6. PubMed ID: 19389820
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy.
    Albright ES, Desmond R, Bell DS.
    Diabetes Care; 2004 Feb; 27(2):632-3. PubMed ID: 14747268
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine.
    Doyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV.
    Diabetes Care; 2004 Jul; 27(7):1554-8. PubMed ID: 15220227
    [Abstract] [Full Text] [Related]

  • 6. Switch to multiple daily injections with insulin glargine and insulin lispro from continuous subcutaneous insulin infusion with insulin lispro: a randomized, open-label study using a continuous glucose monitoring system.
    Bode BW, Steed RD, Schleusener DS, Strange P.
    Endocr Pract; 2005 Jul; 11(3):157-64. PubMed ID: 16239201
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin.
    Porcellati F, Rossetti P, Pampanelli S, Fanelli CG, Torlone E, Scionti L, Perriello G, Bolli GB.
    Diabet Med; 2004 Nov; 21(11):1213-20. PubMed ID: 15498088
    [Abstract] [Full Text] [Related]

  • 10. Treatment with insulin glargine reduces asymptomatic hypoglycemia detected by continuous subcutaneous glucose monitoring in children and adolescents with type 1 diabetes.
    Deiss D, Kordonouri O, Hartmann R, Hopfenmüller W, Lüpke K, Danne T.
    Pediatr Diabetes; 2007 Jun; 8(3):157-62. PubMed ID: 17550426
    [Abstract] [Full Text] [Related]

  • 11. Glycemic parameters with multiple daily injections using insulin glargine versus insulin pump.
    Garg SK, Walker AJ, Hoff HK, D'Souza AO, Gottlieb PA, Chase HP.
    Diabetes Technol Ther; 2004 Feb; 6(1):9-15. PubMed ID: 15000764
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Insulin glargine in the treatment of type 1 and type 2 diabetes.
    Barnett AH.
    Vasc Health Risk Manag; 2006 Feb; 2(1):59-67. PubMed ID: 17319470
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes.
    Hanaire-Broutin H, Melki V, Bessières-Lacombe S, Tauber JP.
    Diabetes Care; 2000 Sep; 23(9):1232-5. PubMed ID: 10977011
    [Abstract] [Full Text] [Related]

  • 16. Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability.
    Pickup JC, Kidd J, Burmiston S, Yemane N.
    Diabetes Metab Res Rev; 2006 Sep; 22(3):232-7. PubMed ID: 16389648
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
    Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB.
    Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
    [Abstract] [Full Text] [Related]

  • 18. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ, Scism-Bacon JL, Zagar AJ.
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of AIR inhaled insulin compared to insulin lispro in patients with type 1 diabetes mellitus in a 6-month, randomized, noninferiority trial.
    Comulada AL, Renard E, Nakano M, Rais N, Mao X, Webb DM, Milicevic Z.
    Diabetes Technol Ther; 2009 Sep; 11 Suppl 2():S17-25. PubMed ID: 19772445
    [Abstract] [Full Text] [Related]

  • 20. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes.
    Hamann A, Matthaei S, Rosak C, Silvestre L, HOE901/4007 Study Group.
    Diabetes Care; 2003 Jun; 26(6):1738-44. PubMed ID: 12766103
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.